Abbott’s Humira Wins European Approval for Ulcerative Colitis By Kristen Hallam - Apr 11, 2012 2:30 PM GMT+0930
Abbott Laboratories (ABT) said the European Commission approved its Humira injection for moderately to severely active ulcerative colitis in adults who haven’t responded well to conventional treatment.
The decision makes Humira the first self-injectable biologic therapy for these patients, Abbott Park, Illinois-based Abbott said today in a statement. It’s the seventh approved use for the drug since it was first cleared in the European Union in 2003, the company said.
Ulcerative colitis is a chronic inflammatory bowel disease that causes ulcers in the colon and may affect as many as 1.2 million people in the EU, according to Abbott
CBZ Price at posting:
7.5¢ Sentiment: Buy Disclosure: Held
